Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lesion-Directed Therapies and Monitoring Tumor Evolution Using Liquid Biopsies.

Cold Spring Harbor perspectives in medicine - 1 Feb 2017

Russo Mariangela, Bardelli Alberto

Abstract excerpt

Precision oncology relies on targeted drugs, such as kinase inhibitors, that are presently administered based on molecular profiles obtained from surgical or bioptic tissue samples. The inherent ability of human tumors to molecularly evolve in response to drug pressures represents a daunting diagnostic challenge. Circulating free DNA (cfDNA) released from primary and metastatic lesions can be used to draw...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to DNA, Neoplasm
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liquid Biopsy

Share to Mutation

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 28003276
DOI: 10.1101/cshperspect.a029587
PMCID: PMC5287059

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lesion-Directed Therapies and Monitoring Tumor Evolution Using Liquid Biopsies.PMID 28003276Read ↗

Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?Semantic proximity Read ↗

Assessing the Concordance of Genomic Alterations between Circulating-Free DNA and Tumour Tissue in Cancer PatientsSemantic proximity Read ↗

The potential of liquid biopsies for the early detection of cancerSemantic proximity Read ↗

Liquid biopsies across the cancer care continuum.Semantic proximity Read ↗

Patient monitoring through liquid biopsies using circulating tumor DNASemantic proximity Read ↗

Clinical applications of cell-free DNA-based liquid biopsy analysisSemantic proximity Read ↗

Treatment response and tumor evolution: lessons from an extended series of multianalyte liquid biopsies in a metastatic breast cancer patient.Semantic proximity Read ↗

Dissecting Tumor Heterogeneity by Liquid Biopsy—A Comparative Analysis of Post-Mortem Tissue and Pre-Mortem Liquid Biopsies in Solid NeoplasiasSemantic proximity Read ↗

Circulating tumor DNA-From bench to bedside.Semantic proximity Read ↗

Circulating Cell-Free DNA—Diagnostic and Prognostic Applications in Personalized Cancer TherapySemantic proximity Read ↗

Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapiesSemantic proximity Read ↗

Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.